Home
/

What is an Atherogenic Coefficient Blood Test?

REVIEWED BY
Bill Maish, MD
Clinical Content Consultant
Published
May 30, 2026
Last updated
May 30, 2026
Quick answer:

The Atherogenic Coefficient (AC) is a calculated ratio—(total cholesterol minus HDL) divided by HDL—that condenses the balance between plaque-promoting lipoproteins and protective HDL into a single cardiovascular risk signal. Values roughly 1–3 are typical; persistently above 3 suggests higher risk. Tracking AC alongside ApoB and triglycerides over time may help support assessment of lipid quality and long-term cardiovascular resilience.

Read more →
Table of contents

Atherogenic Coefficient: A Calculated Lipid Balance Marker

The Atherogenic Coefficient (AC) is a calculated marker from a standard cholesterol blood test, not a substance in the blood. It describes how cholesterol is distributed among lipoproteins. Specifically, it compares the cholesterol carried by potentially plaque-forming particles (non-HDL lipoproteins: LDL, VLDL, IDL, and remnants) to the cholesterol carried by the protective scavenger particle (HDL). The AC is computed using routine values for total cholesterol and HDL cholesterol, drawn from the same sample used for a basic lipid panel.

Biologically, it reflects the balance between cholesterol delivery to tissues and artery walls by apoB-containing particles (atherogenic lipoproteins) and cholesterol removal back to the liver by HDL (reverse cholesterol transport). By condensing this balance into a single ratio, the AC provides a compact view of the atherogenicity of a person's lipid profile. It helps characterize the overall lipoprotein mix and its tendency toward cholesterol deposition versus removal in artery walls.

Why a Single Ratio Sharpens Cardiovascular Risk

The atherogenic coefficient (AC) captures the balance between cholesterol particles that promote plaque and those that help clear it. Calculated as (total cholesterol − HDL cholesterol) divided by HDL cholesterol, it reflects the push–pull between apoB-containing "atherogenic" lipoproteins and HDL-mediated reverse cholesterol transport. It integrates liver metabolism, vascular inflammation, insulin signaling, and hormonal status into one cardiovascular risk signal.

Reading an AC Value Across the Range

Many labs report AC values around 1–3 as typical, with lower values generally indicating lower risk and persistent values above 3 suggesting higher atherogenic burden.

When the value sits toward the lower end, HDL is relatively plentiful or efficient, non-HDL particles are fewer, and cholesterol trafficking favors removal from artery walls. Endothelial tone and nitric oxide signaling are better preserved, so blood pressure regulation and microvascular function tend to be healthier. This state is usually asymptomatic. Premenopausal women commonly have lower AC than men due to higher HDL; children also tend to have lower values unless a familial disorder is present.

Values drifting higher indicate more atherogenic particles relative to HDL, greater endothelial activation, and accelerated plaque formation. People may feel nothing for years, yet subtle signs—reduced exercise tolerance, erectile dysfunction in men, or rising blood pressure—can reflect early vascular stiffness. After menopause, AC often rises in women; during pregnancy, lipids increase physiologically and AC can climb, though marked elevations may signal heightened cardiometabolic strain.

Low values usually reflect low atherogenic particles and/or relatively higher HDL. Physiology points to efficient reverse cholesterol transport and less endothelial stress. Children and premenopausal women commonly sit lower.

High values usually reflect excess LDL/VLDL or low HDL, signaling greater cholesterol deposition, foam-cell formation, and endothelial dysfunction. It commonly tracks with insulin resistance, visceral adiposity, hypothyroidism, kidney or liver disorders, and chronic inflammation. Values tend to be higher in men, rise with age and after menopause, and can increase in late pregnancy due to physiologic hyperlipidemia.

What Can Shift an AC Value

Fasting status, acute illness, and laboratory methods can shift components and the ratio. Many drugs and hormones (statins, fibrates, steroids, androgens/estrogens, beta-blockers, retinoids) alter lipids. Because AC is a ratio, changes may arise from the numerator, denominator, or both; pairing with non-HDL cholesterol or apoB helps provide context. Very low results can also appear with malnutrition, overactive thyroid (thyrotoxicosis), chronic liver disease, or rare genetic hypolipidemias, and occasionally with unusually high but sometimes dysfunctional HDL.

AC links lipid transport, liver and adipose biology, and vascular health. It complements LDL-C, non-HDL-C, triglycerides, and markers of insulin resistance, refining long-term risk for atherosclerotic cardiovascular disease and its downstream effects on heart, brain, kidneys, and metabolic resilience.

What an AC Result Adds to Long-Term Tracking

Being in range suggests a stable lipoprotein mix that supports healthy arterial function, adequate tissue oxygen delivery, and balanced hormone and membrane lipid supply. Epidemiologically, risk tends to fall as AC moves toward the lower end of its reference interval, aligned with favorable non-HDL and apolipoprotein B profiles.

FAQs

It calculates (Total Cholesterol − HDL-C) ÷ HDL-C from a standard lipid panel to show the balance between atherogenic and protective cholesterol.

AC highlights hidden risk when LDL-C appears acceptable but HDL is low or triglycerides are high, and it refines cardiovascular risk beyond LDL-C alone.

Every 3–6 months during active lifestyle or therapy changes, and at least annually for maintenance.

Diet quality, triglycerides, insulin resistance, weight, physical activity, alcohol, thyroid and kidney function, and genetics.

AC comes from a standard lipid panel. If fasting is recommended for triglycerides, follow a 9–12-hour fast.

Superpower currently offers at-home blood testing in the following states: Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Idaho, Illinois, Indiana, Kansas, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, and Wisconsin.

We’re actively expanding nationwide, with new states being added regularly. If your state isn’t listed yet, stay tuned.

References

  1. Millán, J., Pintó, X., Muñoz, A., Zúñiga, M., Rubiés-Prat, J., Pallardo, L. F., Masana, L., Mangas, A., Hernández-Mijares, A., González-Santos, P., Ascaso, J. F., & Pedro-Botet, J. (2009). Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention. Vascular Health and Risk Management, 5, 757-765. https://pubmed.ncbi.nlm.nih.gov/19774217/
  2. Sniderman, A. D., Thanassoulis, G., Glavinovic, T., Navar, A. M., Pencina, M., Catapano, A., & Ference, B. A. (2019). Apolipoprotein B particles and cardiovascular disease: A narrative review. JAMA Cardiology, 4(12), 1287-1295. https://doi.org/10.1001/jamacardio.2019.3780
  3. Emerging Risk Factors Collaboration. (2009). Major lipids, apolipoproteins, and risk of vascular disease. JAMA, 302(18), 1993-2000. https://doi.org/10.1001/jama.2009.1619
  4. Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., Goldberg, R., Heidenreich, P. A., Hlatky, M. A., Jones, D. W., Lloyd-Jones, D., Lopez-Pajares, N., Ndumele, C. E., Orringer, C. E., Peralta, C. A., ... Yeboah, J. (2019). 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol. Circulation, 139(25), e1082-e1143. https://doi.org/10.1161/CIR.0000000000000625
  5. Prospective Studies Collaboration. (2007). Blood cholesterol and vascular mortality by age, sex, and blood pressure: A meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet, 370(9602), 1829-1839. https://doi.org/10.1016/S0140-6736(07)61778-4

Built by the world’s top doctors and scientists

Dr Anant Vinjamoori, MD

Chief Longevity Officer, Superpower

Board-certified longevity physician. Previously product leader at Virta Health & CMO at Modern Age. Featured in  WSJ, Forbes, and Fortune.

Learn more

Dr Leigh Erin Connealy, MD

Clinician & Founder of The Centre for New Medicine

Leads the largest integrative medical clinic in North America. A pioneer in integrative oncology.

Learn more

Dr Robert Lufkin

UCLA Medical Professor, NYT Bestselling Author

A leading voice on metabolic health and longevity as shown in The Today Show, USA Today and FOX.

Learn more

Dr Abe Malkin

Founder & Medical Director of Concierge MD

Leads a nationwide medical practice, and Drip Hydration, a mobile IV therapeutics company

Learn more
Membership slide 1
Membership slide 1
Membership slide 2
Membership slide 3
1 / 3

Your membership starts here

Annual 100+ biomarker panel

Data dashboard and digital twin

Upload past labs and connect wearables

Personalized health protocol

24/7 care team access

AI companion for all health questions

Marketplace with additional solutions

$199

/year*

Billed annually

HSA/ FSA eligible
Cancel anytime
Results in a week

* Pricing may vary for members in New York and New Jersey